Melanie Hullings

2.0k total citations
15 papers, 377 citations indexed

About

Melanie Hullings is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Melanie Hullings has authored 15 papers receiving a total of 377 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pulmonary and Respiratory Medicine, 6 papers in Oncology and 6 papers in Cancer Research. Recurrent topics in Melanie Hullings's work include Prostate Cancer Treatment and Research (7 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Radiopharmaceutical Chemistry and Applications (3 papers). Melanie Hullings is often cited by papers focused on Prostate Cancer Treatment and Research (7 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Radiopharmaceutical Chemistry and Applications (3 papers). Melanie Hullings collaborates with scholars based in United States. Melanie Hullings's co-authors include Howard I. Scher, Ethan Barnett, Emily Carbone, Ryan Dittamore, Ryon P. Graf, Susan F. Slovin, Shirley Bartido, David B. Solit, Nikolaus Schultz and Jason S. Lewis and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Melanie Hullings

15 papers receiving 375 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Melanie Hullings United States 9 206 193 131 104 62 15 377
Giacomo Barchiesi Italy 11 96 0.5× 232 1.2× 88 0.7× 108 1.0× 84 1.4× 22 376
Laura Barker United Kingdom 8 176 0.9× 330 1.7× 71 0.5× 152 1.5× 48 0.8× 17 478
Cédric van Marcke Belgium 12 92 0.4× 156 0.8× 165 1.3× 124 1.2× 16 0.3× 34 370
Rico D. Bense Netherlands 8 166 0.8× 298 1.5× 141 1.1× 177 1.7× 153 2.5× 9 508
Ji Won Woo South Korea 10 58 0.3× 219 1.1× 118 0.9× 82 0.8× 49 0.8× 18 352
Katrin Almstedt Germany 12 95 0.5× 270 1.4× 119 0.9× 125 1.2× 95 1.5× 33 403
Hanne Lind United States 5 128 0.6× 336 1.7× 134 1.0× 150 1.4× 152 2.5× 7 496
Rachel Krupa United States 8 266 1.3× 320 1.7× 250 1.9× 108 1.0× 44 0.7× 26 469
Eugene Kim United States 10 96 0.5× 160 0.8× 109 0.8× 127 1.2× 69 1.1× 24 378
Joanna Niemiec Poland 14 163 0.8× 243 1.3× 134 1.0× 114 1.1× 17 0.3× 47 462

Countries citing papers authored by Melanie Hullings

Since Specialization
Citations

This map shows the geographic impact of Melanie Hullings's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Melanie Hullings with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Melanie Hullings more than expected).

Fields of papers citing papers by Melanie Hullings

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Melanie Hullings. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Melanie Hullings. The network helps show where Melanie Hullings may publish in the future.

Co-authorship network of co-authors of Melanie Hullings

This figure shows the co-authorship network connecting the top 25 collaborators of Melanie Hullings. A scholar is included among the top collaborators of Melanie Hullings based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Melanie Hullings. Melanie Hullings is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Shriver, Sharon P., et al.. (2023). Feasibility of institution‐agnostic, EHR‐integrated regional clinical trial matching. Cancer. 130(1). 60–67. 7 indexed citations
2.
Reddy, Sangeetha M., Isaac S. Chan, Melanie Hullings, et al.. (2022). Phase 1 pilot study with dose expansion of chemotherapy in combination with CD40 agonist and Flt3 ligand in metastatic triple-negative breast cancer.. Journal of Clinical Oncology. 40(16_suppl). TPS1126–TPS1126. 3 indexed citations
3.
Haley, Barbara, Kiran Batra, Sunati Sahoo, et al.. (2021). A Phase I/Ib Trial of PD 0332991 (Palbociclib) and T-DM1 in HER2-Positive Advanced Breast Cancer After Trastuzumab and Taxane Therapy. Clinical Breast Cancer. 21(5). 417–424. 16 indexed citations
4.
Itzstein, Mitchell S. von, Melanie Hullings, Helen Mayo, et al.. (2021). Application of Information Technology to Clinical Trial Evaluation and Enrollment. JAMA Oncology. 7(10). 1559–1559. 15 indexed citations
5.
Stopsack, Konrad H., Subhiksha Nandakumar, Andreas G. Wibmer, et al.. (2020). Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate Cancer. Clinical Cancer Research. 26(13). 3230–3238. 119 indexed citations
6.
Schonhoft, Joseph D., Jimmy L. Zhao, Adam Jendrisak, et al.. (2020). Morphology-Predicted Large-Scale Transition Number in Circulating Tumor Cells Identifies a Chromosomal Instability Biomarker Associated with Poor Outcome in Castration-Resistant Prostate Cancer. Cancer Research. 80(22). 4892–4903. 32 indexed citations
7.
Graf, Ryon P., Melanie Hullings, Ethan Barnett, et al.. (2019). Clinical Utility of the Nuclear-localized AR-V7 Biomarker in Circulating Tumor Cells in Improving Physician Treatment Choice in Castration-resistant Prostate Cancer. European Urology. 77(2). 170–177. 58 indexed citations
8.
Abida, Wassim, Michael L. Cheng, Joshua Armenia, et al.. (2018). Microsatellite instability in prostate cancer and response to immune checkpoint blockade.. Journal of Clinical Oncology. 36(15_suppl). 5020–5020. 10 indexed citations
9.
Rathkopf, Dana E., Karen A. Autio, Emmanuel S. Antonarakis, et al.. (2018). c15-160: Enzalutamide (ENZA) plus CC-115 in men with metastatic castration-resistant prostate cancer (mCRPC): A phase 1b Prostate Cancer Clinical Trials Consortium study.. Journal of Clinical Oncology. 36(15_suppl). 5045–5045. 4 indexed citations
10.
Danila, Daniel C., Timothy M. Kuzel, Jeremy Cetnar, et al.. (2016). A phase 1/2 study combining ipilimumab with abiraterone acetate plus prednisone in chemotherapy- and immunotherapy-naïve patients with progressive metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 34(15_suppl). e16507–e16507. 2 indexed citations
11.
Rathkopf, Dana E., Susan F. Slovin, Karen A. Autio, et al.. (2016). A Phase II Study of the Dual mTOR Inhibitor MLN0128 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC).. Journal of Clinical Oncology. 34(15_suppl). e16529–e16529. 2 indexed citations
12.
Touijer, Karim, Ying‐Bei Chen, Brett S. Carver, et al.. (2014). Establishing a neoadjuvant platform for developing targeted agents: Degarelix prior to prostatectomy for patients with intermediate- and high-risk prostate cancer.. Journal of Clinical Oncology. 32(15_suppl). TPS5105–TPS5105. 2 indexed citations
13.
Slovin, Susan F., Xiuyan Wang, Melanie Hullings, et al.. (2013). Chimeric antigen receptor (CAR+) modified T cells targeting prostate specific membrane antigen (PSMA) in patients (pts) with castrate metastatic prostate cancer (CMPC).. Journal of Clinical Oncology. 31(15_suppl). TPS3115–TPS3115. 30 indexed citations
14.
Slovin, Susan F., Xiuyan Wang, Melanie Hullings, et al.. (2013). Chimeric antigen receptor (CAR+) modified T cells targeting prostate-specific membrane antigen (PSMA) in patients (pts) with castrate metastatic prostate cancer (CMPC).. Journal of Clinical Oncology. 31(6_suppl). 72–72. 59 indexed citations
15.
Pehli̇van, Davut, Melanie Hullings, Claudia M.B. Carvalho, et al.. (2012). NIPBL rearrangements in Cornelia de Lange syndrome: evidence for replicative mechanism and genotype–phenotype correlation. Genetics in Medicine. 14(3). 313–322. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Giacomo Barchiesi Breakdown of academic impact, for papers by Laura Barker Breakdown of academic impact, for papers by Cédric van Marcke Breakdown of academic impact, for papers by Rico D. Bense Breakdown of academic impact, for papers by Ji Won Woo Breakdown of academic impact, for papers by Katrin Almstedt Breakdown of academic impact, for papers by Hanne Lind Breakdown of academic impact, for papers by Rachel Krupa Breakdown of academic impact, for papers by Eugene Kim Breakdown of academic impact, for papers by Joanna Niemiec
Rankless by CCL
2026